p63 and p73 in tumor suppression and promotion.
The recent discovery of two genes, termed p63 and p73, encoding transcription factors highly homologous to p53 presents unexpected challenges and opportunities for the understanding and treatment of cancers. The questions raised are many but center on determining whether these new genes possess novel tumor suppressor functions, cooperate with p53, or impart oncogenic effects. At present there is considerable discord in the field concerning these concepts with some favoring a tumor suppressor role for the p53 family members and others an oncogenic influence. In support of a tumor suppressor role is the ability of p73 and p63 isoforms to transactivate p53 target genes and the large body of work linking p73, and to some extent p63, in apoptotic events in response to cellular stresses generally considered the purview of p53. More recently, p73 has been implicated in cell death following T cell activation, the response of cancers to chemotherapy, and finally, along with p63, to the function of p53 itself. Opposing this view is the fact that the p73 and p63 genes are rarely mutated in cancers and the stark absence of tumors in the p73 null mouse. Moreover, the high expression of dominant negative (dn) versions of the p73 and p63 proteins supports an anti-p53 function and therefore possibly an oncogenic effect. Indeed, the p63 gene is located in a region of chromosome three amplified in squamous cell carcinomas and the number of reports of dn-p63 overexpression in these diseases is increasing. This review will examine both sides of these arguments in an attempt to decipher common themes and to identify opportunities these genes represent for understanding tumorigenesis.
McKeon
Frank D
FD
Department of Cell Biology, Harvard Medical School, USA. fmckeon@hms.harvard.edu
Nat Genet. 2000 May;25(1):47-54
10802655
Cell. 1997 Feb 7;88(3):323-31
9039259
Nat Med. 1998 Jul;4(7):747-8
9662346
Mol Cell Biol. 1999 Feb;19(2):1438-49
9891077
Cancer Cell. 2003 Apr;3(4):403-10
12726865
Eur J Cancer. 1995;31A(4):538-41
7576962
Nature. 2000 Mar 2;404(6773):99-103
10716451
Biochem Biophys Res Commun. 1998 Jul 30;248(3):603-7
9703973
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5462-7
10805802
Nature. 2002 Apr 4;416(6880):560-4
11932750
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):479-84
8552665
Nat Genet. 2000 Dec;26(4):464-9
11101847
Cell. 2000 Mar 31;101(1):91-101
10778859
Nature. 1999 Jun 24;399(6738):814-7
10391251
Nature. 1992 Mar 19;356(6366):215-21
1552940
Apoptosis. 2001 Jun;6(3):173-82
11388666
Nature. 2000 Oct 5;407(6804):642-5
11034214
Nat Cell Biol. 2003 Jun;5(6):552-8
12766778
Cell. 2000 Mar 31;101(1):103-13
10778860
Nature. 2000 Oct 5;407(6804):645-8
11034215
Nature. 1997 Sep 11;389(6647):191-4
9296498
Cancer Cell. 2003 Apr;3(4):387-402
12726864
Cancer Res. 2001 May 15;61(10):4122-9
11358835
Nature. 1999 Jun 24;399(6738):734-5, 737
10391235
Mamm Genome. 1998 Nov;9(11):899-902
9799841
Nature. 1999 Jun 24;399(6738):806-9
10391249
Science. 2000 Jul 14;289(5477):304-6
10894779
Nature. 1999 Apr 22;398(6729):714-8
10227294
Nature. 1999 Jun 24;399(6738):809-13
10391250
Nat Rev Mol Cell Biol. 2000 Dec;1(3):199-207
11252895
Cell. 1997 Aug 22;90(4):809-19
9288759
Hum Pathol. 2003 Sep;34(9):850-6
14562279
Trends Genet. 2002 Feb;18(2):90-5
11818141
Mol Cell. 1998 Sep;2(3):305-16
9774969
Nat Med. 1998 Jul;4(7):839-43
9662378